Imagery Rescripting and Imaginal Exposure for Social Anxiety: Mechanisms and Outcomes in an Analog Sample
Launched by HEBREW UNIVERSITY OF JERUSALEM · Nov 13, 2020
Trial Information
Current as of May 23, 2025
Unknown status
Keywords
ClinConnect Summary
After being informed about the study potential risks, all patients giving written informed consent will undergo screening to determine eligibility for study entry. They will be randomly assigned to two conditions (Imagery rescripting Vs. Imaginal exposure) at a 1:1 ratio. Participants will attend three \~1 hour online ZOOM sessions (pre-assessment and measurement, intervention, and post assessment and measurement).
Assessors will be blind to the treatment condition.
Gender
ALL
Eligibility criteria
- • Inclusion Criteria: SPIN scores \>= 30 -
- Exclusion Criteria:
- • can't report a negative imagery related to a future social scenario. Attending active psychotherapy sessions.
- • -
About Hebrew University Of Jerusalem
The Hebrew University of Jerusalem, a leading academic institution in Israel, is renowned for its cutting-edge research and innovation in various fields, including medicine and life sciences. With a commitment to advancing healthcare, the university actively sponsors clinical trials that aim to explore novel therapeutic interventions and improve patient outcomes. Leveraging its multidisciplinary expertise and state-of-the-art facilities, the Hebrew University fosters collaboration among researchers, clinicians, and industry partners to translate scientific discoveries into practical applications, thereby enhancing the quality of care and contributing to the global medical community.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Jerusalem, , Israel
Patients applied
Trial Officials
Jonathan D Huppert, PhD
Principal Investigator
Professor
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials